90.02MMarket Cap-511P/E (TTM)
12.8200High12.2700Low11.72KVolume12.4450Open12.6400Pre Close147.11KTurnover0.28%Turnover RatioLossP/E (Static)7.04MShares24.400052wk High0.69P/B53.94MFloat Cap10.000052wk Low--Dividend TTM4.22MShs Float382.6000Historical High--Div YieldTTM4.35%Amplitude8.0000Historical Low12.5490Avg Price1Lot Size
Cidara Therapeutics Stock Forum
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics (CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
No comment yet